477 related articles for article (PubMed ID: 29941047)
1. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
Lovell DJ; Dare JA; Francis-Sedlak M; Ball J; LaMoreaux BD; Von Scheven E; Reinhardt A; Jerath R; Alpan O; Gupta R; Goldsmith D; Zeft A; Naddaf H; Gottlieb B; Jung L; Holt RJ
Pediatr Rheumatol Online J; 2018 Jun; 16(1):41. PubMed ID: 29941047
[TBL] [Abstract][Full Text] [Related]
2. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
Angiolillo DJ; Datto C; Raines S; Yeomans ND
J Thromb Thrombolysis; 2014 Jul; 38(1):11-23. PubMed ID: 24368727
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
Wang-Smith L; Fort J; Zhang Y; Sostek M
J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.
Ruperto N; Nikishina I; Pachanov ED; Shachbazian Y; Prieur AM; Mouy R; Joos R; Zulian F; Schwarz R; Artamonova V; Emminger W; Bandeira M; Buoncompagni A; Foeldvari I; Falcini F; Baildam E; Kone-Paut I; Alessio M; Gerloni V; Lenhardt A; Martini A; Hanft G; Sigmund R; Simianer S;
Arthritis Rheum; 2005 Feb; 52(2):563-72. PubMed ID: 15692986
[TBL] [Abstract][Full Text] [Related]
6. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.
Sostek MB; Fort JG; Estborn L; Vikman K
Curr Med Res Opin; 2011 Apr; 27(4):847-54. PubMed ID: 21319944
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
[TBL] [Abstract][Full Text] [Related]
9. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
Cryer BL; Sostek MB; Fort JG; Svensson O; Hwang C; Hochberg MC
Ann Med; 2011 Dec; 43(8):594-605. PubMed ID: 22017620
[TBL] [Abstract][Full Text] [Related]
10. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
[TBL] [Abstract][Full Text] [Related]
11. Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib.
Holt RJ; Fort JG; Grahn AY; Kent JD; Bello AE
Phys Sportsmed; 2015 Jul; 43(3):200-12. PubMed ID: 26313454
[TBL] [Abstract][Full Text] [Related]
12. Naproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers.
Dhillon S
Drugs Aging; 2011 Mar; 28(3):237-48. PubMed ID: 21329403
[TBL] [Abstract][Full Text] [Related]
13. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
[TBL] [Abstract][Full Text] [Related]
14. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Yeomans ND; Graham DY; Husni ME; Solomon DH; Stevens T; Vargo J; Wang Q; Wisniewski LM; Wolski KE; Borer JS; Libby P; Lincoff AM; Lüscher TF; Bao W; Walker C; Nissen SE;
Aliment Pharmacol Ther; 2018 Jun; 47(11):1453-1463. PubMed ID: 29667211
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic comparison study of a combination containing 500 mg of Naproxen and 20 mg of Esomeprazole: a randomized, single-dose, 2-way crossover, open-label study in healthy Korean men.
Choi HG; Jeon JY; Kwak SS; Kim H; Jin C; Im YJ; Kim EY; Wang HM; Kim Y; Lee SY; Kim MG
Clin Ther; 2015 Jan; 37(1):83-93. PubMed ID: 25482305
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone.
Goldstein JL; Hochberg MC; Fort JG; Zhang Y; Hwang C; Sostek M
Aliment Pharmacol Ther; 2010 Aug; 32(3):401-13. PubMed ID: 20497139
[TBL] [Abstract][Full Text] [Related]
18. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
19. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis.
Foeldvari I; Szer IS; Zemel LS; Lovell DJ; Giannini EH; Robbins JL; West CR; Steidle G; Krishnaswami S; Bloom BJ
J Rheumatol; 2009 Jan; 36(1):174-82. PubMed ID: 19012356
[TBL] [Abstract][Full Text] [Related]
20. Naproxen/esomeprazole (Vimovo).
Med Lett Drugs Ther; 2010 Sep; 52(1347):74-5. PubMed ID: 20847717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
